Institutional members access full text with Ovid®

Share this article on:

Hair Loss in Patients with Inflammatory Bowel Disease

Patel, Kamal V. BSc, MBBS, MRCP*; Farrant, Paul BSc, MBBS, MRCP; Sanderson, Jeremy D. MD, FRCP*; Irving, Peter M. MA, MD, FRCP*

doi: 10.1097/MIB.0b013e31828132de
Clinical Review Articles

Background: Little is known about the prevalence, causes, and management of hair loss in patients with inflammatory bowel disease (IBD). Despite the fact that there are relatively few case reports describing hair loss in IBD, anecdotally, it is a common clinical problem. Hair loss is associated with both acute and chronic illness, with nutritional deficiencies, and with adverse drug reactions, all of which are relevant to IBD.

Methods: A literature search was performed using PubMed from 1966 to July 2012 to identify all articles describing cases of and/or the cause of hair loss in patients with IBD.

Results: There is relatively little data describing the prevalence, cause, or course of hair loss in people with IBD. Because there are many potential reasons for hair loss in people with IBD, identifying the cause is not always possible. Telogen effluvium associated with acute or chronic flares of IBD is probably the commonest cause of disease-related hair loss, although the prevalence of this is unknown. Other causes include drug side effects and nutritional deficiencies. More recently shared genetic risk factors with alopecia areata and IBD have been identified.

Conclusions: The potential causes of hair loss in IBD are protean, although its prevalence is unknown. A practical guide to assessing and managing patients with hair loss in IBD is presented.

Article first published online 24 April 2013

*Department of Gastroenterology, Guy’s and St Thomas’ Hospital, London, United Kingdom; and

Department of Dermatology, Brighton and Sussex University Hospitals Trust, United Kingdom.

Reprints: Peter M. Irving, Department of Gastroenterology, First Floor College House, St Thomas’ Hospital, Westminster Bridge Road, London SE1 7EH, United Kingdom (e-mail: peter.irving@gstt.nhs.uk).

The authors have no conflicts of interest to disclose.

Received September 17, 2012

Accepted September 23, 2012

© Crohn's & Colitis Foundation of America, Inc.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website